treatment of pah associated with ipf/ssc
DESCRIPTION
Treatment of PAH Associated with IPF/SSc. Dr.Özlem Özdemir Kumbasar. Clinical Classification of Pulmonary Hypertension. 1-Pulmonary arterial hypertension 2-Pulmonary hypertension associated with left heart diseases 3-Pulmonary hypertension associated with respiratory diseases and/or hypoxia - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/1.jpg)
1
Treatment of PAH Associated with IPF/SSc
Dr.Özlem Özdemir Kumbasar
![Page 2: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/2.jpg)
2
Clinical Classification of Pulmonary Hypertension
1-Pulmonary arterial hypertension 2-Pulmonary hypertension associated
with left heart diseases 3-Pulmonary hypertension associated
with respiratory diseases and/or hypoxia 4-Pulmonary hypertension due to chronic
thrombotic and/or embolic disease 5-Miscellaneaus
![Page 3: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/3.jpg)
3
1.Pulmonary Arterial Hypertension
1.1.Idiopathic 1.2.Familial 1.3.Associated with
1.3.1.Connective tissue diseases 1.3.2.Congenital systemic to pulmonary shunts 1.3.3.Portal hypertension 1.3.4.HIV infection 1.3.5.Drugs and toxins 1.3.6.Other (tyroid disorders, hematological problems….)
1.4.Associated with significant venous or capillary involvement
1.5.Persistant pulmonary hypertension of the newborn
![Page 4: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/4.jpg)
4
3.Pulmonary hypertension associated with respiratory diseases and/or hypoxia
3.1.Chronic obstructive pulmonary diseases
3.2.Interstitial lung diseases 3.3.Sleep disordered breathing 3.4.Alveolar hypoventilation disorders 3.5.Chronic exposure to high altitude 3.6.Developmental abnormalities
![Page 5: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/5.jpg)
5
Systemic sclerosis-Scleroderma
American Rheumatism Association (American College of Rheumatology):Major criterion or two or more minor criterion
Major criterion: symmetrical thickening, thightening and induration of the skin of the fingers and skin proximal to the metacarpophalangeal, or metatarsophalengeal joints
Minor criteria: Sclerodactily: the changes of the major criterion, but
limited to the fingers Digital pitting scars or loss of substance from the finger
pad: depressed areas at tips of fingers or loss of digital pad tissue as a result of ischemia
Bibasilar pulmonary fibrosis
![Page 6: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/6.jpg)
6
SSc has two subgroups according to the extent of skin involvement: Diffuse SSc-dSSc Limited SSc-lSSc
![Page 7: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/7.jpg)
7
Pulmonary manifestations of scleroderma
Most common manifestations: Interstitial lung disease Pulmonary hypertension
Others: Pleural disease Chronic aspiration Airway disease Lung cancer Extrinsic restriction
![Page 8: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/8.jpg)
8
PH in SSc ILD hypoxemia PH ILD+PH (PH out of proportion to the degree of
fibrosis) Isolated PH Myocardial inflammation and fibrosis
left and right ventricular disfunctionPH
-PH due to unrelated lung disease (COPD, CTEPH)
![Page 9: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/9.jpg)
9
PAH is a leading cause of mortality in SSC.
SSc-associated PAH has got a worse prognosis than idiopathic PAH.
PAH related to SSc is common but its true prevelance is not known (4.9-38%)
![Page 10: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/10.jpg)
10
Risk factors for PAH in SSc Genetic???: HLA-B*13; HLA-B*65 Increased age of SSc onset;
postmenopausal age Severe Raynaud phenomenon and
digital tip ulcers Absence of anti-Scl-70 Predominance of nucleolar auto-
antibodies
![Page 11: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/11.jpg)
11
A decrease of DLCO during the early stages of the disease is a predictor of subsequent development of PAH during the course of SSc.
![Page 12: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/12.jpg)
12
Pathogenesis Pathogenesis of SSc-PAH resemble those
of iPAH: Endothelial injury dysfunction
activated myofibroblasts Overproduction of endothelin Decreased production of vasodilators Vascular smooth muscle cell proliferation and
hypertrophy Inflammation and adventitial fibrosis in
medium sized to small sized pulmonary arteries
Vasoconstriction and hypertrophic changes increased pulmonary vascular resistance
![Page 13: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/13.jpg)
13
Clinical features
Symptoms are often nonspecific: dyspnea fatigue chest pain syncope
In the early stages symptoms are evident only on exertion.
![Page 14: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/14.jpg)
14
Diagnosis-baseline
History Examination Blood tests Autoantibodies Chest x-ray PFT (spirometry, DLCO, ABG) Doppler Echo
![Page 15: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/15.jpg)
15
Scleroderma patient with respiratory symptoms
PFT : spirometry, DLCO, ABG Isolated reduction in DLCO or a
proggressive decline in DLCO suggest PAH A ratio of percentage of predicted FVC and
the percentage of predicted DLCO >1.4 is a predictor of PAH; and a value >2 predicts worse survival.
Normal PFT results do not rule out PAH. Serial DLCO testing has been recommended
![Page 16: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/16.jpg)
16
Doppler Echo sPAP>35mmHg ? - >40mmHg
N-terminal proBNP CT-pericardial disease, main pA
daimeter >29mm Right heart catheterization-gold
standard
![Page 17: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/17.jpg)
17
Treatment Patients with combined PAH and diastolic
dysfunction and/or interstitial lung disease are often exclude from clinical trials. Therefore it is not known how best to treat them.
Treatment may be complicated with worsening hypoxemia due to increased ventilation-perfusion mismatch or pulmonary edema in patients with severe honeycombing or diastolic dysfunction.
![Page 18: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/18.jpg)
18
Treatment
There are no specific guidelines for the treatment of SSc-PAH.
Treatment guidelines for iPAH cover PAH associated with connective tissue diseases; most experts use these recommendations.
![Page 19: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/19.jpg)
19
Treatment All patients with documented
hypoxemia should be on supplemental oxygen to maintain SaO2 above 90%.
Patients with evidence of right ventricular failure should be given diuretics.
Oral anticoagulant- can be given if complication risk is low. Bleeding complications are more frequent in SSc.
![Page 20: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/20.jpg)
20
Treatment CCB:
Less than 10% of patients with iPAH are true responders to high dose calcium channel blokers.
Even fewer patients with SSc-PAH are true responders.
Acute vasoreactivity testing for Patients with SSc-PAH (weak recommendation based on expert opinion only)
![Page 21: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/21.jpg)
21
Treatment
PAH specific agents: Prostanoids Endothelin antagonists Phosphodiesterase inhibitors
![Page 22: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/22.jpg)
22
Treatment
Prostanoids: Epoprostenol:
Continuous iv epoprostenol improved exercise capacity, symptoms and hemodynamics in patients with SSc-PAH, in a multicenter, randomised, controlled, open label study . A survival advantage was not demonstrated.
![Page 23: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/23.jpg)
23
Treatment
Prostanoids: Treprostinil:
Sc infusion of treprostinil improved symptoms, exercise capacity and hemodynamics in patients with CTD related PAH
Inhaled iloprost: Inhaled iloprost trial included patients with
CTD, but subgroup analysis for thie group was not reported.
![Page 24: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/24.jpg)
24
Treatment
Endothelin antagonists: Bosentan:
It is approved for the treatment of iPAH and CTD-PAH.
Bosentan prevented walk distance deterioration in patients with SSc when compared with placebo. But exercise improvement was less marked than that seen in iPAH population.
![Page 25: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/25.jpg)
25
Treatment Bosentan:
In a retrospective single center study of iPAH and SSc-PAH patients, firs-line bosentan monotherapy was associated with long term improvement in functional class and good overall survival in patients with class III iPAH. Bur SSc-PAH patients showed stability or decline in functional class and tended to have a higher mortality.
In a second retrospective study of SSc-PAH patients bosentan was associated with an early improvement in functional class, but this benefit was lost after 9 months.
![Page 26: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/26.jpg)
26
Treatment
Efficacy of selective ETA receptor antagonists sitaxsentan and ambrisentan in SSc-PAH patients remains to be determined
![Page 27: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/27.jpg)
27
Treatment
Phosphodiesterase inhibitors: Sildenafil:
In a randomised, double-blind, placebo controlled study of 278 patients with PAH sildenafil improved exercise capacity, functional class and hemodynamics. 30% of these patients had CTD, mainly SSc; but subgroup analysis was not reported.
![Page 28: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/28.jpg)
28
Updated ACCP Guideline-Chest 2007:131:1917-1928
![Page 29: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/29.jpg)
29
PAH is a leading cause of mortality in patients with SSc.
In the current treatment era, 1 year survival for patients with SSc-PAH improved from 68 to 81%; and 2 year survival from 47 to 71%.
But SSc-PAH is associated with a poorer response to therapy and worse outcome when compared with iPAH.
![Page 30: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/30.jpg)
30
Idiopathic Pulmonary Fibrosis
IPF has a poor prognosis. Median survival is 2-5 years. Mortality is usually related to
progressive restriction or acute exacerbations.
PH may complicate the course of IPF and potentially impact prognosis.
![Page 31: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/31.jpg)
31
Prognostic factors in IPF
10% decrements in FVC Exercise capacity
6 MW distance Desaturation during 6 MWT
PH
![Page 32: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/32.jpg)
32
PH in IPF
Prevalence: 32-85% Serial progression in PAP Retrospective studies:
Initial prevelance: 33-41% Follow-up prevalence:85-90%
![Page 33: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/33.jpg)
33
PH in IPF Lung volumes PH Exercise capacity PH Interstitial remodeling Vascular remodeling
Down-regulation of prostanoid synthases in the interstitium and pulonary arteries of patients with IPF???
IPF lungs show increased ET-1 and ET converting enzyme as compared with normal lungs
PDGF TGF-beta
![Page 34: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/34.jpg)
34
PH in IPF Presence of PH correlated with lower DLCO
and requirement for supplemental oxygen. PH appears to be an important prognostic
factor in IPF. sPAP>50mmHg was found correlated with
poorer survival. Patients with mean PAP>35 had 1.5 fold
increased post lung transplant mortality.
![Page 35: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/35.jpg)
35
Treatment
Supplemental oxygen-beneficial effects on survival?
CCB-no role Anticoagulation-better outcomes
with long term anticoagulation??
![Page 36: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/36.jpg)
36
Treatment Bosentan
BUILD-1:A randomized placebo controlled trial of bosentan in idiopathic pulmonary fibrosis
No improvment over placebo with respect to 6MWD
A trend to delayed time to death or disease progression
Patients with echocardiographic evidence of severe PH (sPAP>50) were excluded.
![Page 37: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/37.jpg)
37
Treatment
iv epoprostenol: Decreases mPAP but increases
pulmonary shunt flow Current data do not support the use
of iv epoprostenol in PH related to IPF
![Page 38: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/38.jpg)
38
Treatment
Inhaled iloprost Decreases mPAP without changes in
shunt flow in patients with PH related to lung fibrosis. (8 patients, only one of them IPF).
Inhaled iloprost in IPF+PH-this study was completed (www.clinicaltrials.gov) Results?
![Page 39: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/39.jpg)
39
Treatment
Sildenafil A sigle dose of sildenafil decreased
mPAP and shunt flow A study with 14 patients: sildenafil
improved 6MWD
![Page 40: Treatment of PAH Associated with IPF/SSc](https://reader035.vdocuments.net/reader035/viewer/2022062519/56814c50550346895db9609f/html5/thumbnails/40.jpg)
40
Treatment There are potential therapies: Et
antagonists, inhaled prostanoids, phosphodiesterase inhibitors
But long term randomized, controlled trials are necessary to make strict conclusions.
Supplemental oxygen (when necessary) the most important therapy according to current data.